QQQ   267.64 (-0.99%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
QQQ   267.64 (-0.99%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
QQQ   267.64 (-0.99%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
QQQ   267.64 (-0.99%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
Log in

NASDAQ:DRRXDURECT Stock Price, Forecast & News

$2.33
-0.01 (-0.43 %)
(As of 08/11/2020 03:14 PM ET)
Add
Compare
Today's Range
$2.33
Now: $2.33
$2.40
50-Day Range
$1.94
MA: $2.20
$2.50
52-Week Range
$0.95
Now: $2.33
$3.95
Volume43,895 shs
Average Volume1.46 million shs
Market Capitalization$467.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Read More
DURECT logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRRX
CUSIPN/A
Phone408-777-1417

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.56 million
Book Value$0.12 per share

Profitability

Net Income$-20,580,000.00

Miscellaneous

Employees88
Market Cap$467.35 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$2.33
-0.01 (-0.43 %)
(As of 08/11/2020 03:14 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DURECT (NASDAQ:DRRX) Frequently Asked Questions

How has DURECT's stock price been impacted by Coronavirus (COVID-19)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRRX shares have increased by 41.2% and is now trading at $2.33.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DURECT?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DURECT
.

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for DURECT
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its earnings results on Monday, August, 3rd. The specialty pharmaceutical company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. DURECT had a negative net margin of 3.66% and a negative return on equity of 7.69%.
View DURECT's earnings history
.

What price target have analysts set for DRRX?

6 brokerages have issued twelve-month price objectives for DURECT's shares. Their forecasts range from $2.10 to $7.00. On average, they anticipate DURECT's stock price to reach $5.02 in the next twelve months. This suggests a possible upside of 115.5% from the stock's current price.
View analysts' price targets for DURECT
.

What are Wall Street analysts saying about DURECT stock?

Here are some recent quotes from research analysts about DURECT stock:
  • 1. According to Zacks Investment Research, "Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations. " (5/8/2020)
  • 2. HC Wainwright analysts commented, "Recently Signed Gilead Partnership Yields First $10M Milestone; Affirm Buy Gilead rapidly advances long-acting injectible HIV drug based on SABER agreement. Yesterday, DURECT announced that it has earned a $10M milestone payment from Gilead (GILD; not rated) related to the further development of an investigational injectable HIV product utilizing DURECT’s SABER technology, as part of a license agreement that was announced in July 2019. In addition to the $25M upfront payment already received, remaining milestones include the potential for up to an additional $65M in development and regulatory milestones, up to an additional $70M in sales-based milestones, as well as tiered royalties on product sales." (9/10/2019)

Has DURECT been receiving favorable news coverage?

Headlines about DRRX stock have trended neutral this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DURECT earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about DURECT
.

Are investors shorting DURECT?

DURECT saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 6,420,000 shares, an increase of 51.4% from the January 31st total of 4,240,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the short-interest ratio is currently 4.1 days. Approximately 3.5% of the shares of the stock are sold short.
View DURECT's Short Interest
.

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Cassava Sciences (SAVA), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), Verastem (VSTM), Amarin (AMRN), CymaBay Therapeutics (CBAY), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Who are DURECT's key executives?

DURECT's management team includes the following people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
  • Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
  • Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (3.97%), Beirne Wealth Consulting Services LLC (1.01%), Swiss National Bank (0.22%), DAVENPORT & Co LLC (0.17%), Mackay Shields LLC (0.14%) and WINTON GROUP Ltd (0.13%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe, Judy R Joice, Lp Bleichroeder and Michael Arenberg.
View institutional ownership trends for DURECT
.

Which major investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, and Ingalls & Snyder LLC. Company insiders that have sold DURECT company stock in the last year include Judy R Joice, and Lp Bleichroeder.
View insider buying and selling activity for DURECT
.

Which major investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including Swiss National Bank, Mackay Shields LLC, New York State Common Retirement Fund, SG Americas Securities LLC, Principal Financial Group Inc., State Board of Administration of Florida Retirement System, Beirne Wealth Consulting Services LLC, and UBS Group AG. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder, and Michael Arenberg.
View insider buying and selling activity for DURECT
.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $2.33.

How big of a company is DURECT?

DURECT has a market capitalization of $467.35 million and generates $29.56 million in revenue each year. The specialty pharmaceutical company earns $-20,580,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. DURECT employs 88 workers across the globe.

What is DURECT's official website?

The official website for DURECT is www.durect.com.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.